Top performance algorithms for the detection of extremely short episodes of atrial fibrillation (AF) from the electrocardiogram. We have also developed methods able to detect AF in patients with regular ventricular response.
Risk stratification of patients undergoing catheter ablation, which is currently considered as a first-line therapy to atrial fibrillation. This stratification evaluates the individualized risk of AF maintenance after the procedure.
Development on energy-based ablative techniques such as radiofrequency, microwave, laser, etc., using computer modeling, bench test based on ex vivo models, preclinical studies, based on in vivo models, and clinical trials.
Envision of the response to pharmacological or electrical cardioversion therapies in AF. Cardioversion is a frequent therapy to revert persistent AF but its success rates are limited and the risks are relevant.
Most part of the results on energy-based techniques are being transferred to Apeiron Medical, a start-up company which commercialces the COOLINSIDE patented technology.
Anticipation of paroxysmal AF episodes by predicting their onset with a clinically useful advance of, at least, 90 minutes. Thus, pharmacological interventions and hospitalization should be possible to react against the forthcoming arrhythmic event.
The Cox-Maze surgery is one of the most effective treatments to terminate AF, but a reliable preoperative prediction of the surgery outcome can guide proper selection of patients undergoing surgery, thus reducing costs for the health system and risks for the patient.